ENTERA BIO LTD. (ENTX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 2.10M USD | Liabilities, Current |
| Cash and equivalents | 11.31M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.10M | $11.31M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $1.58M | $4.14M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $2.20M | $7.11M | (m) | $0.00 | (m) | (m) |
| 2025-09-30 | (m) | $1.57M | $8.57M | (m) | $0.00 | (m) | (m) |
| 2025-06-30 | (m) | $1.84M | $10.86M | (m) | $0.00 | (m) | (m) |
| 2025-03-31 | (m) | $1.62M | $12.57M | (m) | $126.00K | (m) | (m) |
| 2024-12-31 | (m) | $1.18M | $8.66M | (m) | $126.00K | (m) | (m) |
| 2024-09-30 | (m) | $1.11M | $6.92M | (m) | $42.00K | (m) | (m) |
| 2024-06-30 | (m) | $1.29M | $9.06M | (m) | $57.00K | (m) | (m) |
| 2024-03-31 | (m) | $1.12M | $9.19M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $1.09M | $11.02M | (m) | $0.00 | (m) | (m) |
| 2023-09-30 | (m) | $2.03M | $7.58M | (m) | $0.00 | (m) | (m) |
| 2023-06-30 | (m) | $1.86M | $9.13M | (m) | $29.00K | (m) | (m) |
| 2023-03-31 | (m) | $1.49M | $10.69M | (m) | $29.00K | (m) | (m) |
| 2022-12-31 | (m) | $1.34M | $12.31M | (m) | $246.00K | (m) | (m) |
| 2022-09-30 | (m) | $1.19M | $14.32M | (m) | $233.00K | (m) | (m) |
| 2022-06-30 | (m) | $1.69M | $17.28M | (m) | $225.00K | (m) | (m) |
| 2022-03-31 | (m) | $2.33M | $20.11M | (m) | $210.00K | (m) | (m) |
| 2021-12-31 | (m) | $3.16M | $24.89M | (m) | $183.00K | (m) | (m) |
| 2021-09-30 | (m) | (m) | $27.39M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $26.93M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $16.38M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $1.84M | $8.59M | (m) | $255.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |